相关实验视频

Updated: May 6, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

在高果糖养小鼠中,LDT409 (泛PPAR部分激动剂) 减轻了与代谢功能障碍相关的脂肪性肝病

Aline Fernandes-da-Silva¹, Daiana Araujo Santana-Oliveira¹, Andressa S de Oliveira²

¹Laboratory of Morphometry, Metabolism, and Cardiovascular Diseases, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

Molecular and cellular endocrinology

|September 27, 2024

概括

从果仁废弃物中提取的LDT409,通过改善能量代谢和减少小鼠内质网膜 (ER) 应激,有效地对抗高果糖诱导的肝脏问题.

科学领域:

生物化学生物化学
代谢研究的研究.
肝病学肝病学是一种肝病学.

背景情况:

高果糖饮食诱导胰岛素耐药性和肝脏内质网膜 (ER) 的压力.
肝脏肥胖症和纤维化是由改变的PPAR (Peroxisome Proliferator-Activated Receptor) 基因表达加剧的.
与代谢功能障碍相关的脂肪性肝病缺乏特定的治疗干预措施.

研究的目的:

为了研究LDT409的治疗潜力,一种新的泛PPAR部分激动剂,对肝脏健康.
在高果糖小鼠模型中评估LDT409对肝脏重塑,能量代谢和ER压力的影响.
探索LDT409涉及PPAR-alpha和PPAR-gamma通路的作用机制.

主要方法:

雄性C57BL/6小鼠在10周内接受了控制或高果糖饮食.
饮食期结束后,小鼠接受了为期五周的控制饮食或LDT409 (40 mg/kg) 治疗.
基因表达分析和代谢标记被评估以评估肝脏健康和ER压力.

主要成果:

高果糖饮食诱导了显著的胰岛素抵抗和ER压力.
LDT409治疗减轻了肝肥胖症和亲纤维基因基因表达.
LDT409的好处与抑制的脂质因子 (PPAR-) 和增强的β-氧化 (PPAR-α) 相关,缓解ER压力.

结论:

LDT409在改善高果糖诱导的肝损伤方面显示出显著的潜力.
这种化合物可能为与代谢功能障碍相关的脂肪性肝病提供成本有效的治疗策略.
LDT409的作用包括调节PPARs调节的关键代谢途径.

关键词:

压力ERER压力ERER压力果糖是葡萄糖中的一种果糖.LDT4099 这是一本书.马斯尔德马斯尔德是什么意思这是一种PPAR-Alpha.在PPAR-Gamma中使用.

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...